이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Invivyd 대차 대조표 상태

재무 상태 기준 확인 5/6

Invivyd 의 총 주주 지분은 $178.5M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $215.5M 및 $37.0M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$189.39m
주식	US$178.50m
총 부채	US$36.97m
총 자산	US$215.47m

최근 재무 상태 업데이트

Recent updates

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Mar 29

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Oct 24

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Jul 04

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Mar 19

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Nov 19

Invivyd appoints interim CFO, makes headcount changes

Oct 13

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Sep 12

Adagio Therapeutics GAAP EPS of -$0.47

Aug 15

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Jul 30

Adagio names David Hering as permanent CEO and Director

Jul 05

Adagio's Round Trip

Mar 02

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Feb 19

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Feb 16

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Nov 29

재무 상태 분석

단기부채: IVVD 의 단기 자산 ( $209.9M )이 단기 부채( $36.3M ).

장기 부채: IVVD 의 단기 자산( $209.9M )이 장기 부채( $625.0K ).

부채 대 자본 내역 및 분석

부채 수준: IVVD 부채가 없습니다.

부채 감소: IVVD 지난 5년간 부채가 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: IVVD 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: IVVD 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

Invivyd 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Recent updates

Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd, Inc. Announces Management Changes

Invivyd, Inc. Elects Two New Independent Members to its Board of Directors

Forecast to breakeven in 2026

Invivyd, Inc. to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Invivyd, Inc., Annual General Meeting, May 21, 2024

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda

Invivyd, Inc. Announces CEO Changes

Invivyd, Inc. Announces CEO Transition

New minor risk - Profitability

No longer forecast to breakeven

Consensus revenue estimates fall by 13%

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Forecast breakeven date moved forward to 2025

Invivyd, Inc. Provides Earnings Guidance for the Year 2024

Consensus revenue estimates increase by 64%

Is Invivyd (NASDAQ:IVVD) In A Good Position To Invest In Growth?

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

New minor risk - Shareholder dilution

Forecast to breakeven in 2026

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19

Invivyd, Inc. Appoints William Duke as Chief Financial Officer

Invivyd, Inc. Appoints Sara Cotter to Board of Directors

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd, Inc. Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222

Will Invivyd (NASDAQ:IVVD) Spend Its Cash Wisely?

Invivyd, Inc. Announces Executive Changes

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Invivyd, Inc

Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer

Is Invivyd (NASDAQ:IVVD) In A Good Position To Deliver On Growth Plans?

Less than half of directors are independent

Invivyd Announces Board Changes

Invivyd, Inc. Announces Executive Changes

Invivyd appoints interim CFO, makes headcount changes

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in Vitro Data Against Omicron Variants

Adagio Therapeutics changes name to Invivyd, generates COVID-19 antibodies

Adagio Therapeutics GAAP EPS of -$0.47

We're Keeping An Eye On Adagio Therapeutics' (NASDAQ:ADGI) Cash Burn Rate

Adagio Therapeutics, Inc. Appoints David Hering Permanent Chief Executive Officer

Less than half of directors are independent

Adagio names David Hering as permanent CEO and Director

Howard Mayer, M.D. Notifies Adagio Therapeutics, Inc. of His Decision to Resign from the Board of Directors

Adagio Therapeutics, Inc.(NasdaqGM:ADGI) dropped from Russell 2000 Growth Index

Adagio Therapeutics, Inc. Elects Class I Directors

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Adagio Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

No longer forecast to breakeven

Mithril Capital Provides Information to Shareholders of Adagio Therapeutics

Adagio Therapeutics, Inc. Provides Update on Timing of Adintrevimab EUA Request

No longer forecast to breakeven

No longer forecast to breakeven

Mithril Capital Management Communicates with Adagio Therapeutics

Adagio Therapeutics, Inc. Announces Executive Changes, Effective March 25, 2022

Adagio's Round Trip

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

Adagio Therapeutics, Inc. Announces Executive Changes

We're Interested To See How Adagio Therapeutics (NASDAQ:ADGI) Uses Its Cash Hoard To Grow

Adagio: A COVID-19 Play With Big Potential On Possible Treatment And Prevention

Adagio Therapeutics, Inc. Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

Adagio Therapeutics: The Market Is Too Crowded For Its Lead Drug Candidate

Adagio Therapeutics, Inc. Reports Updates on Its Lead Covid-19 Antibody Program, ADG20

Adagio Therapeutics, Inc. Announces the Independent Data Monitoring Committee (IDMC) for the EVADE Phase 2/3 Trial of ADG20 for the Prevention of COVID-19

Adagio Therapeutics, Inc. has completed an IPO in the amount of $309.4 million.

재무 상태 분석